Viking Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
-- VANQUISH Phase 3 Trials for Subcutaneous VK2735 in Obesity Continue to Advance -- -- SUNRISE Phase 3 Trials for Oral VK2735 Initiated -- -- Positive Top-Line Results Announced for VK2735 Maintenance Dosing Study; Part 2 Study Initiated -- -- Phase 1 SAD Study of Amylin Agonist VK3019...
Covered in this story
Call it yourself
No calls on $TOP yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on TOP Financial Group →Dalsna Finance is currently tracking 24 stories mentioning TOP Financial Group, the earliest published 5 Jun 2026.
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.